

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Emergent BioSolutions Inc.</u>  (Last) (First) (Middle) 400 PROFESSIONAL DRIVE, SUITE 400  (Street) GAITHERSBURG MD 20879  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 05/23/2019	3. Issuer Name and Ticker or Trading Symbol <u>Emergent BioSolutions Inc. [ EBS ]</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) Sean Kirk, EVP, Manufacturing	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	13,604 <sup>(1)</sup>	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Stock Options (Right to Buy)	(2)	02/28/2023	Common Stock	3,135	30.86	D
Stock Options (Right to Buy)	(2)	02/27/2024	Common Stock	7,293	30.63	D
Stock Options (Right to Buy)	(2)	02/26/2025	Common Stock	6,044	49.64	D
Stock Options (Right to Buy)	(2)	02/25/2026	Common Stock	5,124	61.01	D
Stock Options (Right to Buy)	(2)	03/31/2026	Common Stock	1,424	50.52	D

Explanation of Responses:

- Consists of 2,933 shares, as well as 1,424 unvested PSUs and 9,247 unvested RSUs granted from the Emergent Stock Incentive Plan. Each RSU and each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2021 fiscal year, as certified by the Compensation Committee following the performance period. The RSUs vest in three equal installments annually on the day prior to the anniversary date of the grant.
- Vests in three equal annual installments beginning on the day prior to the anniversary date of the grant.

Remarks:

Exhibit List: Exhibit-24.1 Power of Attorney

/s/ S. Scott Lieberman, Attorney-in-fact

06/03/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY  
FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Atul Saran, Brian Millard and Scott Lieberman signing singly and each of them jointly and severally, to (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including but not limited to, (2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Emergent BioSolutions Inc. (the "Company"), Forms 3, 4, and 5, (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such Form 3, 4, and 5, (4) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company's securities from any 10b-5 plan, (5) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney in fact, may be of benefit to, in the best interests of, and for the benefit of the Company. The undersigned hereby grants to each such attorney in fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, and proper to carry out the foregoing, and This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's securities. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 30th day of May 2019.

By: /s/ Sean Kirk

Name: Sean Kirk